AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
NVDA   350.66 (-0.03%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
BAC   26.78 (+3.04%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
NVDA   350.66 (-0.03%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
BAC   26.78 (+3.04%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
NVDA   350.66 (-0.03%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
BAC   26.78 (+3.04%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
NVDA   350.66 (-0.03%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
BAC   26.78 (+3.04%)
Log in

NASDAQ:SGMOSangamo Therapeutics Stock Price, Forecast & News

$11.22
-0.30 (-2.60 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.14
Now: $11.22
$11.79
50-Day Range
$7.15
MA: $9.35
$11.83
52-Week Range
$4.81
Now: $11.22
$13.33
Volume110,257 shs
Average Volume2.28 million shs
Market Capitalization$1.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.26
Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation. Its therapeutic products which are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; SB-FIX for the treatment of hemophilia B; ST-400 for the treatment of beta-thalassemia; and SB-318 for the treatment of Mucopolysaccharidosis Type I and SB-913 for the treatment of Mucopolysaccharidosis Type II, which are lysosomal storage disorders (LSDs). The company also develops ST-920, a gene therapy for fabry disease. It has collaboration and license agreements with Kite Pharma, Inc., Pfizer Inc., Bioverativ Inc., and Shire International GmbH, as well as license partnerships with Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Read More
Sangamo Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGMO
CUSIP80067710
Phone510-970-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$102.43 million
Book Value$3.73 per share

Profitability

Net Income$-95,190,000.00

Miscellaneous

Employees302
Market Cap$1.58 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive SGMO News and Ratings via Email

Sign-up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions

How has Sangamo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Sangamo Therapeutics' stock was trading at $7.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SGMO stock has increased by 60.0% and is now trading at $11.23. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Sangamo Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sangamo Therapeutics.

When is Sangamo Therapeutics' next earnings date?

Sangamo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Sangamo Therapeutics.

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics Inc (NASDAQ:SGMO) released its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.14. The biopharmaceutical company earned $13.10 million during the quarter, compared to the consensus estimate of $22.73 million. Sangamo Therapeutics had a negative return on equity of 22.68% and a negative net margin of 89.31%. The business's quarterly revenue was up 61.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.41) earnings per share. View Sangamo Therapeutics' earnings history.

What price target have analysts set for SGMO?

3 equities research analysts have issued 1-year price targets for Sangamo Therapeutics' shares. Their forecasts range from $10.00 to $16.00. On average, they anticipate Sangamo Therapeutics' stock price to reach $13.00 in the next year. This suggests a possible upside of 15.8% from the stock's current price. View analysts' price targets for Sangamo Therapeutics.

Has Sangamo Therapeutics been receiving favorable news coverage?

Headlines about SGMO stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Sangamo Therapeutics earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutSangamo Therapeutics.

Who are some of Sangamo Therapeutics' key competitors?

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Micron Technology (MU), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Alibaba Group (BABA), Editas Medicine (EDIT) and Intel (INTC).

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the following people:
  • Dr. Alexander D. Macrae, CEO, Pres & Director (Age 56)
  • Ms. Kathy Y. Yi, EVP, CFO, Principal Accounting Officer & Sec. (Age 47)
  • Dr. Edward R. Conner, Sr. VP & Chief Medical Officer (Age 46)
  • Dr. Edward Rebar, Sr. VP & CTO
  • Mr. McDavid Stilwell, VP of Corp. Communications & Investor Relations

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.07%), Wasatch Advisors Inc. (5.11%), State Street Corp (4.17%), Tang Capital Management LLC (1.44%), Geode Capital Management LLC (1.45%) and Alexandria Capital LLC (0.86%). Company insiders that own Sangamo Therapeutics stock include Edward R Conner, H Stewart Parker, Joseph S Zakrzewski, Kathy Yi and Stephen George Dilly. View institutional ownership trends for Sangamo Therapeutics.

Which major investors are selling Sangamo Therapeutics stock?

SGMO stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Deutsche Bank AG, Morgan Stanley, Morgan Stanley, BNP Paribas Arbitrage SA, BlackRock Inc., Rafferty Asset Management LLC, and Nuveen Asset Management LLC. View insider buying and selling activity for Sangamo Therapeutics.

Which major investors are buying Sangamo Therapeutics stock?

SGMO stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Two Sigma Investments LP, JPMorgan Chase & Co., Bailard Inc., Senvest Management LLC, SG Americas Securities LLC, Two Sigma Advisers LP, and 361 Capital LLC. Company insiders that have bought Sangamo Therapeutics stock in the last two years include H Stewart Parker, and Joseph S Zakrzewski. View insider buying and selling activity for Sangamo Therapeutics.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $11.23.

How big of a company is Sangamo Therapeutics?

Sangamo Therapeutics has a market capitalization of $1.58 billion and generates $102.43 million in revenue each year. The biopharmaceutical company earns $-95,190,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. Sangamo Therapeutics employs 302 workers across the globe.

What is Sangamo Therapeutics' official website?

The official website for Sangamo Therapeutics is www.sangamo.com.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.